An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
NCT ID: NCT01483898
Last Updated: 2021-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
41 participants
INTERVENTIONAL
2012-02-29
2014-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
NCT00468000
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)
NCT01245335
Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)
NCT00498069
Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization
NCT00987363
Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
NCT02538978
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ixmyelocel-T
Ixmyelocel-T
On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
Placebo
Placebo
On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ixmyelocel-T
On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
Placebo
On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 35 to 90 years of age
* Diagnosis of CLI with tissue loss (corresponding to Rutherford Category 5; see Appendix B) having an ulcer size of at least 0.5 cm2, a smaller sized ulcer penetrating into the subcutaneous tissue, and/or gangrene (dry). In addition, the subject must have ONE of the following documented at screening:
* Ankle systolic pressure \< 70 mm Hg
* Toe systolic pressure \< 50 mm Hg
* TcPO2 \< 30 mm Hg (in a supine position)
* Subjects must have no reasonable standard-of-care options for surgical or endovascular revascularization interventions
* Subjects must have the following:
* A narrative documenting the reasons why the site vascular specialist considers the subject "no option". A vascular specialist will be the principal investigator (PI) or subinvestigator and is defined as: vascular surgeon, interventional cardiologist, certified vascular medicine specialist, or interventional radiologist; AND
* Secondary confirmation by an independent Eligibility Review Committee (ERC; see Section 8.1) after review of appropriate documents including, but not limited to: imaging results, medical records, surgical history, site vascular specialist narrative documenting reasons for "no option," and/or lab reports.
* Major amputation in the index leg or death is not anticipated within 3 months of screening in the opinion of the vascular specialist (who must be the PI or subinvestigator)
* In the opinion of the investigator, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance)
* Subject is current with all age-appropriate American Cancer Society (ACS) or similar (e.g., United States Preventative Service Task Force) screening guidelines
* Given medical history and concurrent medication, the subject is an acceptable candidate for bone marrow aspiration and intramuscular injection procedures in the opinion of the Investigator
* Subject is willing and able to comply with the scheduled visits, aspiration/injection procedure, wound care instructions treatment plan, and other study procedures for the duration of the study
* Provide a personally-signed and dated informed consent document indicating that the subject (or a legally-acceptable representative, if permitted by the site's Investigational Review Board \[IRB\]) has been informed of all pertinent aspects of the study
Exclusion Criteria
Disease-specific:
* Failed open surgical revascularization (on index leg) within 4 weeks of screening Visit 1
* Acute limb-threatening ischemia, trauma, known non-atherosclerotic vascular disease (e.g., temporal/giant cell arteritis, Takayasu's arteritis, Raynaud's occlusive disease, Buerger's disease), embolic disease, aortoiliac disease with \> 50% stenosis, or history of hypercoagulable states
* Advanced CLI (i.e., nonsalvageable) defined as Rutherford Category 6
* Clinical evidence of invasive infection in index leg (e.g., cellulitis, osteomyelitis, wet gangrene)
* At screening, non-heel wound size of \> 20 cm2 (excluding toe gangrene); or wounds on the heel \> 10 cm2 on the index leg as measured by the Wound Core Lab (WCL) from photographs (and/or acetates) provided by the site
* Previous amputation at or above the talus in the index leg Medical History
* Hemoglobin A1c (HbA1c) ≥ 10% at screening
* Diabetic subjects with uncontrolled or untreated proliferative retinopathy as determined by dilated eye exam (by qualified eye care professional as per American Diabetes Association guidelines)
* Blood clotting disorder not caused by medication (e.g., thrombophilia)
* Active non-basal cell cutaneous malignancy requiring surgery, chemotherapy, and/or radiation in the past 12 months
* Current documented drug or alcohol abuse that would interfere with the subject's compliance with study procedures
* Known allergies to any equine, porcine, or bovine products
* Body mass index (BMI) ≥ 50 kg/m2 at screening
* Established chronic kidney disease (CKD) requiring dialysis (Stage 5); estimated creatinine clearance \< 15 mg/mL/min at screening
* Systolic blood pressure (SBP) \> 200 mm Hg or diastolic blood pressure (DBP) \> 120 mm Hg or papilledema noted via ophthalmoscope at screening physical exam
* Within 3 months prior to screening, a clinically significant history of cardiac disease
Laboratory Parameters:
* Abnormal laboratory values (performed at central lab) at screening:
* Platelets \< 50,000 μL
* Aspartate aminotransferase/alanine aminotransferase (AST/ALT) \> 3 times the upper limit of normal (ULN)
* Human immunodeficiency virus 1 (HIV 1), HIV 2, or syphilis positive (rapid plasma reagin \[RPR\])
* Active hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV); Exclusionary Procedures, Devices, or Medication
* Exposure to immunosuppressive therapy for oncologic or chronic non-oncologic reasons in the prior 12 months or expected requirement over the course of the study (e.g., chemotherapy, radiation therapy, methotrexate)
* Concurrent participation in another clinical trial or receiving experimental medication within 30 days of screening or having previously been exposed to Aastrom's ixmyelocel T product \[previously known as tissue repair cells (TRC), cardiac repair cells (CRC), vascular repair cells (VRC)\]
* On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new, nonstandard-of-care treatments to the index leg during the study
35 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vericel Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology PC
Birmingham, Alabama, United States
Cardio-Thoracic Surgeons, P.C.
Birmingham, Alabama, United States
University Of Alabama At Birmingham
Birmingham, Alabama, United States
Arizona Heart Institute
Phoenix, Arizona, United States
Carl T. Hayden VA Medical Center
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
Arkansas Primary Care Clinic, P.A.
Little Rock, Arkansas, United States
Central Arkansas Veteran's Healthcare System
Little Rock, Arkansas, United States
John Muir Medical Center - Concord Campus
Concord, California, United States
VA Loma Linda Healthcare
Loma Linda, California, United States
UCLA Gonda Venous Center & Ambulatory Procedure Unit
Los Angeles, California, United States
Sutter Medical Group - Cardiology
Sacramento, California, United States
University of California San Diego Medical Center
San Diego, California, United States
Kaiser Permanente Medical Center
San Diego, California, United States
University of California San Francisco - Division of Vascular and Endovascular Surgery
San Francisco, California, United States
University of Colorado Denver - Anschutz Medical Campus
Aurora, Colorado, United States
Yale School of Medicine
New Haven, Connecticut, United States
Bethesda Memorial Hospital - Clinical Research Center
Boynton Beach, Florida, United States
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Florida Research Network, LLC
Gainesville, Florida, United States
Malcom Randall Veterans Affairs Medical Center
Gainesville, Florida, United States
First Coast Cardiovascular Institute, P.A.
Jacksonville, Florida, United States
University of Miami Hospital
Miami, Florida, United States
Orlando Health
Orlando, Florida, United States
Baptist Hospital
Pensacola, Florida, United States
Cardiology Consultants
Pensacola, Florida, United States
Grove Place Surgery Center
Vero Beach, Florida, United States
Vascular Surgical Associates, P.C.
Marietta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Illinois at Chicago - Clinical Sciences North
Chicago, Illinois, United States
Memorial Medical Center
Springfield, Illinois, United States
Indiana/Ohio Heart
Fort Wayne, Indiana, United States
St. Vincent Medical Group, Inc.
Indianapolis, Indiana, United States
Heartland Vascular Medicine and Surgery
Windsor Heights, Iowa, United States
Ochsner Clinic foundation
New Orleans, Louisiana, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Union Memorial Hospital
Baltimore, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Boston Medical Center
Boston, Massachusetts, United States
UMASS Memorial Health Care
Worcester, Massachusetts, United States
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States
Cardiology and Vascular Associates, P.C.
Berkley, Michigan, United States
Oakwood Hospital and Medical Center
Dearborn, Michigan, United States
John D. Dingell VA Medical Center
Detroit, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Michigan Vascular Research Center
Flint, Michigan, United States
Integrated Vascular Vein Center of Michigan
Grand Blanc, Michigan, United States
Michigan CardioVascular Institutue at Covenant Medical Center
Saginaw, Michigan, United States
Saint Joseph Mercy Hospital
Ypsilanti, Michigan, United States
Abbott Northwestern Hospital / Minneapolis Heart Institute-Vascular Clinic
Minneapolis, Minnesota, United States
Minneapolis VA Health Care System
Minneapolis, Minnesota, United States
University of Minnesota Medical School
Minneapolis, Minnesota, United States
Hattiesburg Clinic, P.A.
Hattiesburg, Mississippi, United States
Saint Luke's Hospital
Kansas City, Missouri, United States
Omaha VAMC
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Vascular Access Center of West Orange
West Orange, New Jersey, United States
University of Buffalo Surgeons Inc.
Buffalo, New York, United States
Mount Sinai Medical Center
New York, New York, United States
Stony Brook University Medical Center
Stony Brook, New York, United States
University of North Carolina Hospital
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
University Hospitals Case Medical Center
Cleveland, Ohio, United States
Jobst Vascular Institute
Toledo, Ohio, United States
University of Toledo Medical Center
Toledo, Ohio, United States
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Veterans' Administration Medical Center
Pittsburgh, Pennsylvania, United States
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
DFW Vascular Group, LLP
Dallas, Texas, United States
Texas Heart Institute at St. Luke's Episcopal Hospital
Houston, Texas, United States
The Methodist Hospital
Houston, Texas, United States
Audie L Murphy VA Hospital - Pathology Laboratory
San Antonio, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Swedish Medical Center
Seattle, Washington, United States
University of Washington
Seattle, Washington, United States
Cascade Vascular Associates, P.S.
Tacoma, Washington, United States
Charleston Area Medical Center - Memorial Hospital
Charleston, West Virginia, United States
University of Wisconsin
Madison, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Columbia Saint Mary's
Milwaukee, Wisconsin, United States
Wheaton Franciscan Medical Group, Inc.
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Aastrom Biosciences Homepage
Vascular Disease Foundation
Peripheral Arterial Disease Coalition
Vascular web provided by The Society for Vascular Surgery
Legs For Life
University of California, Davis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABI 55-1009-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.